At Padgett Medical Center, patients using personalized compounded semaglutide* and personalized compounded tirzepatide* achieved impressive results in as little as 6–10 months. But which option is right for you?
If you’ve been researching medical weight loss, you’ve likely come across two leading options: semaglutide and tirzepatide.
Both are powerful injectable medications designed to reduce appetite, improve metabolism, and support long-term weight loss—but they work a little differently.
At Padgett Medical Center in Tampa and Ocala, we’ve seen firsthand how effective these treatments can be. In fact, results from our in-clinic study showed:
- Average 20% weight loss with personalized compounded semaglutide*
- Average 22% weight loss with personalized compounded tirzepatide*
- Results achieved over 6–10 months across 50 patients
So… which one is right for you? Let’s break it down.
Personalized compounded semaglutide* is a GLP-1 receptor medication that helps regulate appetite and blood sugar levels.
Benefits:
- Strong appetite suppression
- Proven weight-loss results
- Typically lower starting cost
- Once-weekly injection
This option is often ideal for patients who want a reliable, effective, and more budget-friendly starting point.
Personalized compounded tirzepatide* is a dual-action medication, targeting both GLP-1 and GIP receptors.
Benefits:
- Strong appetite suppression
- Enhanced metabolic support
- Often produces greater total weight loss
- May improve insulin sensitivity more significantly
- Once-weekly injection
This option is often chosen by patients looking for more aggressive or accelerated results.
Side By Side: Key Differences
Mechanism
Semaglutide: GLP-1 only
Tirzepatide: GLP-1 + GIP
Weight Loss Potential
Tirzepatide often shows slightly higher results
Appetite Control
Both are effective, Tirzepatide may feel stronger for some
Metabolic Benefits
Tirzepatide may provide additional improvements
Real Patient Results at Padgett Medical Center
and Which Treatment Is Right for You?
Unlike generic online claims, these results come directly from patients treated in our clinic:
- Study Size: 50 patients
- Duration: 6–10 months
- Average Weight Loss:
- 20% with personalized compounded semaglutide*
- 22% with personalized compounded tirzepatide*
These results highlight how both options can be highly effective when paired with proper medical guidance and personalized dosing.
Choosing between personalized compounded semaglutide and tirzepatide depends on several factors:
Personalized Compounded Semaglutide* may be right if you:
- Want a more cost-effective option
- Prefer a proven, steady approach
- Are new to medical weight loss
Personalized Compounded Tirzepatide* may be right if you:
- Want maximum weight loss potential
- Have struggled with other programs
- Are looking for stronger metabolic support
The best choice ultimately comes down to your goals, medical history, and how your body responds.
Start Your Personalized Weight Loss Plan Today
At Padgett Medical Center, every program is tailored to the individual. Whether you choose semaglutide or tirzepatide, your treatment plan is designed to help you achieve safe, sustainable results.
Frequently Asked Questions
Semaglutide targets GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors, offering a dual-action approach.
Both are highly effective, but tirzepatide may produce slightly greater weight loss in some patients.
In our clinic study, patients lost an average of 20–22% of their starting weight over 6–10 months.
Both medications are widely used under medical supervision and are considered safe when prescribed appropriately.
Both semaglutide and tirzepatide are typically administered once per week.
What are you waiting for?
* Compounded semaglutide and tirzepatide are compounded drugs that have not been approved by the FDA; have not been reviewed by the FDA for safety, effectiveness, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use; the processes by which the compounded drugs are manufactured have not been reviewed by the FDA; and FDA-approved products containing semaglutide and tirzepatide are available. However, the processes by which drugs are compounded are reviewed and regulated by the State Board of Pharmacy under the US Pharmacopeia standards for sterile compounding.
